A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

The purpose of this study is to evaluate the safety and clinical activity of tislelizumab (an anti-PD-1 antibody) in combination with SX-682 (a CXCR1/2 inhibitor) in subjects with newly diagnosed and surgically resectable pancreatic adenocarcinoma.

Trial Details

NCT ID
NCT05604560
Phase
PHASE2
Sponsor
Lei Zheng
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Tislelizumab
  • SX-682
Locations (sample)
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • San Antonio, Texas, United States|29.42412,-98.49363

Key Eligibility Criteria

  • Ability to understand and willingness to sign a written informed consent document.
  • Age ≥18 years.
  • Newly diagnosed have histologically or cytologically proven adenocarcinoma of the pancreas.
  • Tumor must be resectable.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →